Auris Medical Holding AG (NASDAQ:EARS) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.09, MarketWatch Earnings reports.
Auris Medical Holding AG (NASDAQ EARS) traded down 3.40% during midday trading on Thursday, reaching $0.76. 261,871 shares of the company’s stock traded hands. The firm’s market cap is $33.69 million. Auris Medical Holding AG has a 52-week low of $0.60 and a 52-week high of $5.45. The firm’s 50-day moving average is $0.80 and its 200 day moving average is $0.82.
EARS has been the subject of several analyst reports. Roth Capital initiated coverage on shares of Auris Medical Holding AG in a research note on Thursday, April 13th. They issued a “buy” rating and a $4.50 price objective for the company. ValuEngine lowered shares of Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $3.42.
COPYRIGHT VIOLATION WARNING: “Auris Medical Holding AG (NASDAQ:EARS) Issues Quarterly Earnings Results” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2799422/auris-medical-holding-ag-nasdaqears-issues-quarterly-earnings-results.html.
A number of hedge funds and other institutional investors have recently modified their holdings of EARS. Sabby Management LLC purchased a new position in shares of Auris Medical Holding AG during the first quarter valued at about $133,000. Perceptive Advisors LLC purchased a new position in shares of Auris Medical Holding AG during the first quarter valued at about $368,000. Finally, UBS Oconnor LLC purchased a new position in shares of Auris Medical Holding AG during the first quarter valued at about $909,000. 29.05% of the stock is owned by institutional investors and hedge funds.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.